The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2020 | Future research to improve predictive factors for smoldering myeloma
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the focus of research over the next 5 years to improve prediction in smoldering myeloma. There will be developments in genomic, microenvironmental and epigenetic factors to add to the arsenal of clinical factors. Dynamic factors will also need to be further understood to more accurately describe the progression of the disease. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.
